SAN DIEGO--Structural Bioinformatics (SBI) here and BioChem Therapeutics, a wholly owned subsidiary of Biochem Pharma, Laval, Quebec, have agreed to collaborate on drug discovery and design using SBI's proprietary computational technologies. SBI will apply its genomics-driven, protein-structure-based drug design algorithms to facilitate the design and identification of small molecules for two targets selected by BioChem. BioChem will contribute drug development expertise, fund the research, and make milestone and royalty payments.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.